Breakthrough Integrin-regulating Therapy for Ocular Health
Risuteganib regulates mitochondrial dysfunction and downregulates oxidative stress response to restore retinal homeostasis
Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress.
Risuteganib is an integrin-regulating therapy that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis.1
a Animal retinopathy of prematurity [ROP] models
b Genomic analysis
1. Kaiser PK. Topline results from a prospective, double-masked, placebo-controlled phase-2b clinical study evaluating ALG-1001 (Luminate) in patients with diabetic macular edema. ARVO, May 2017.
b Genomic analysis
1. Kaiser PK. Topline results from a prospective, double-masked, placebo-controlled phase-2b clinical study evaluating ALG-1001 (Luminate) in patients with diabetic macular edema. ARVO, May 2017.
